Follicular lymphoma at diagnosis, treated in first line with immunochemotherapy

We performed targeted NGS in Follicular lymphoma samples at diagnosis. Explored clinico-genetic correlations and assessed four clinical or clinicogenetic risk models (FLIPI, FLIPI-2, PRIMA-IP or m7-FLIPI-molecular score) in patients with symptomatic FL who received frontline immunochemotherapy. Out of 191 patients with FL grade 1-3a, 109 were successfully genotyped. Treatment consisted on rituximab (R) plus CVP/CHOP (72.5%) or R-bendamustine (R-B) (27.5%).

Type: Other
Archiver: European Genome-Phenome Archive (EGA)

1 Dataset 1 Publication

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD00001009647	We performed targeted NGS in Follicular lymphoma samples at diagnosis. Explored clinico-genetic correlations and assessed four clinical or clinicogenetic risk models (FLIPI, FLIPI-2, PRIMA-IP or m7-FLIPI-molecular score) in patients with symptomatic FL who received frontline immunochemotherapy. Out of 191 patients with FL grade 1-3a, 109 were successfully genotyped. Treatment consisted on rituximab (R) plus CVP/CHOP (72.5%) or R-bendamustine (R-B) (27.5%).	NextSeq 500	109

Publications	Citations
Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Rodríguez-Sevilla JJ, Fernández-Rodríguez C, Bento L, Diez-Feijóo R, Pinzón S, Gibert J, Fernández-Ibarrondo L, Lafuente M, Ferrer A, Sánchez-González B, Gimeno E, Sainz J, Ramos R, García JF, Colomo L, Bellosillo B, Gutiérrez A, Salar A. Blood Adv 7: 2023 1606-1614	3